{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:07Z","timestamp":1787026627518,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare autoinflammatory disorder characterized by osteoarticular and cutaneous manifestations. While tumor necrosis factor-alpha (TNF-\u03b1) inhibitors such as adalimumab are increasingly used for refractory cases, some patients exhibit inadequate response. Janus kinase (JAK) inhibitors have emerged as a potential alternative, but data on the selective JAK1 inhibitor upadacitinib in SAPHO syndrome are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>An 18-year-old male presented with a 7-year history of recurrent facial acne since 2016. Whole-body bone scintigraphy revealed focally increased radiotracer uptake in the right clavicle, consistent with SAPHO syndrome. Initial treatment of acne with adapalene gel combined with oral minocycline failed to improve skin symptoms, leading to the decision to ultimately pursue biologic therapy. After four months of adalimumab therapy, the patient initially showed improvement in chest pain and dermatitis but subsequently experienced paradoxical worsening of facial acne accompanied by erythema and pruritus. No improvement was observed after an additional four weeks of continued adalimumab treatment. Following a transition to upadacitinib, facial lesions improved within 4 weeks and achieved marked resolution by 8 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report of upadacitinib in SAPHO syndrome demonstrates its rapid and substantial efficacy in a patient refractory to adalimumab. Upadacitinib may represent a promising treatment option for difficult-to-treat SAPHO syndrome, particularly in cases with inadequate response to TNF-\u03b1 inhibition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1818236","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:22:55Z","timestamp":1776403375000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Successful treatment of SAPHO syndrome refractory to adalimumab with upadacitinib"],"prefix":"10.3389","volume":"17","author":[{"given":"Jinwan","family":"Du","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Liangjiang Hospital of Chongqing Medical University, People\u2019s Hospital of Chongqing Liangjiang New Area","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeshan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Chinese Pharmacy, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Geng","sequence":"additional","affiliation":[{"name":"School of Life Science, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shike","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine Rehabilitation, Liangjiang Hospital of Chongqing Medical University, People\u2019s Hospital of Chongqing Liangjiang New Area","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2013.02.009","article-title":"SAPHO syndrome","volume":"39","author":"Carneiro","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-016-0583-y","article-title":"SAPHO syndrome: current developments and approaches to clinical treatment","volume":"18","author":"Firinu","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.97394","article-title":"SAPHO syndrome: pathogenesis, clinical presentation, imaging, comorbidities and treatment: a review","volume":"38","author":"Przepiera-B\u0119dzak","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae114","article-title":"Current and future advances in practice: SAPHO syndrome and chronic non-bacterial osteitis (CNO)","volume":"8","author":"Furer","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"B5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13052-020-00933-1","article-title":"SAPHO syndrome: the supposed trigger by isotretinoin, the efficacy of adalimumab and the specter of depressive disorder: a case report","volume":"46","author":"Luzzati","year":"2020","journal-title":"Ital J Pediatr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s384346","article-title":"SAPHO syndrome with palmoplantar pustulosis as the first manifestation successfully treated with adalimumab","volume":"15","author":"Yang","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05322-x","article-title":"The effectiveness of treatments for patients with SAPHO syndrome: a follow-up study of 24 cases from a single center and review of literature","volume":"40","author":"Huang","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s353539","article-title":"New insights in the treatment of SAPHO syndrome and medication recommendations","volume":"15","author":"Cheng","year":"2022","journal-title":"J Inflammation Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2017.04.010","article-title":"SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes","volume":"85","author":"Berthelot","year":"2018","journal-title":"Joint Bone Spine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14930","article-title":"JAKi: can it be used to treat SAPHO syndrome","volume":"27","author":"Yue","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.09.030","article-title":"Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib","volume":"97","author":"Yang","year":"2018","journal-title":"Med (Balt)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217250","article-title":"Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3095","article-title":"Tofacitinib for the treatment of nail lesions and palmoplantar pustulosis in synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome","volume":"157","author":"Li","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.monrhu.2011.04.002","article-title":"SAPHO syndrome","volume":"54","author":"Hayem","year":"2004","journal-title":"Rev Prat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1662675","article-title":"Upadacitinib in the treatment of SAPHO syndrome: a case report","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70305","article-title":"Case report: successful treatment of secukinumab-induced SAPHO syndrome with tofacitinib","volume":"28","author":"Li","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1745464","article-title":"Case report: successful management of refractory SAPHO syndrome with guselkumab-upadacitinib combination","volume":"17","author":"Jin","year":"2026","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1947601910397187","article-title":"Jak\/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies","volume":"1","author":"Jatiani","year":"2010","journal-title":"Genes Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/1568026619666190620155613","article-title":"Research progress on clinical application and adverse reactions of JAK inhibitors","volume":"57","author":"Liu","year":"2022","journal-title":"Acta Univ Med Anhui"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.105","article-title":"Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors","volume":"31","author":"Bertsias","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000539207","article-title":"Etiological insights of acne in atopic dermatitis patients under upadacitinib treatment: an exploratory study","volume":"37","author":"Muzy","year":"2024","journal-title":"Skin Pharmacol Physiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1818236\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:22:57Z","timestamp":1776403377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1818236\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1818236"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1818236","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1818236"}}